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Patients with severe mental disorders, including schizophrenia and BD, have been found to be at increased risk of cardiovascular and metabolic morbidity and mortality. [7] [8] [9] Two population-based, long-term follow-up studies of patients with schizophrenia and BD have revealed a two-to threefold increase in the rates of death from cardiovascular and endocrine causes. 8, 9 The excess number of deaths attributable to cardiovascular and endocrine disease in these populations is on par with the number of unexpected deaths due to suicide. The results of these studies primarily reflect patient care during the conventional antipsychotic era (1973 to 1995) and support the findings of previous smaller studies. 7, 10 Data on increased morbidity are similarly concerning and have important implications for health service delivery. Higher rates of ventricular arrhythmias (RR 2.3; 95%CI, 1.2 to 4.3), heart failure (RR 1.6; 95%CI, 1.2 to 2.0), stroke (RR 1.5; 95%CI, 1.2 to 2.0), and diabetes (RR 1.8; 95%CI, 1.2 to 2.6) have been observed in patients with schizophrenia. 10 The prevalences of obesity (21% to 49%), smoking (54% to 68%), diabetes mellitus (8% to 17%), hypertension (35% to 39%), and dyslipidemia (23%) significantly exceed those in the general population. 11 The recent transition in antipsychotic prescribing to newer atypical agents, together with their recognized adverse metabolic profile, has increased concerns regarding the physical health of patients taking antipsychotics. In response, guidelines and programs have been developed to improve the detection, monitoring, and treatment of physical illnesses, especially cardiovascular and metabolic disorders, in individuals with serious mental disorders. [12] [13] [14] [15] However, several barriers exist that interfere with the rapid adoption of new monitoring guidelines, including communication, training, equipment, and system limitations in most mental health clinics.
This study was completed to assess the metabolic health of our mental health clinic outpatients taking antipsychotics and to compare the screening, monitoring, and management of metabolic risk factors and diseases in this clinic population with that in a non-mental health care specialty clinic.
Methods

Design and Participants
We undertook a retrospective chart review for the Queen Elizabeth II Health Science Centre Mental Health Outpatient Department Clinic patients who were taking antipsychotic drugs long-term. The same chart review was performed for HIV clinic patients taking HAART at the same institution. This comparison group was selected because it had several key similarities to patients of the mental health clinic. In both clinics, care was provided by an interdisciplinary team to a group of outpatients who had a similar age distribution and were taking drugs known to adversely affect cardiovascular risk factors. Neither clinic was primarily focused on metabolic disorders, although both patient groups have been shown to be at increased risk for CAD (the 10-year CAD risk is 8.8% in HIV patients taking HAART and 9.3% in schizophrenia patients, compared with about 7% in the general population). 16, 17 The primary endpoint of the study was the proportion of patients for whom a 10-year CAD risk estimate could be calculated from information documented in the outpatient chart (that is, age, sex, total serum cholesterol, serum high-density lipoprotein, smoking status, and systolic blood pressure). 18 The secondary endpoints included documented rates of blood glucose, hemoglobin A 1C , weight, BMI, and waist circumference; the charted prevalence of metabolic risk factors and diseases (that is, smoking status, dyslipidemia, hypertension, diabetes mellitus, and CAD); and the screening and monitoring practices for metabolic risk factors and diseases.
Patients from the mental health clinic were eligible if they were at least 18 years of age; diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder NOS, or BD; and taking antipsychotic drugs long-term (that is, for 3 months or more). The observation period was July 1, 2002 , to June 30, 2005 . Patients had to be actively followed by a psychiatrist at the mental health clinic with at least 2 visits yearly and a minimum follow-up period of 6 months. Patients were excluded if they were diagnosed with HIV or were enrolled in another study that required additional monitoring. Patients from the HIV clinic were aged 18 years or older, HIV positive, taking HAART long-term (for 3 months or more), and actively followed by an HIV clinic physician. They were excluded if they were diagnosed with a chronic mental disorder (specifically, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder NOS, or BD), were receiving an antipsychotic drug, were actively followed by the mental health clinic, or were enrolled in another study that required additional monitoring. A list of all eligible cases (determined on the basis of age, diagnosis, and visit dates) was provided from the mental health clinic patient database. We then selected cases for screening at random from this list. Owing to the smaller number of HIV-positive patients and the absence of an electronic database, all eligible patients from the HIV clinic were screened alphabetically for inclusion.
Data Collection
Information was gathered to a maximum of 3 years of individual outpatient data. To reflect information available to outpatient clinicians, relevant findings were recorded from inpatient data only when they were available in the outpatient chart (for example, discharge summaries). We did not use inpatient charts to gather data. Data gathered for each participant included demographic information, diagnoses, medications, smoking status, waist circumference, serum lipid levels, blood pressure, serum glucose, and hemoglobin A 1C . We also recorded the follow-up period and the frequency of outpatient visits. The time to gather risk information (that is, weight, smoking status, lipid profile, blood pressure, serum glucose, and hemoglobin A 1C ) was recorded for a subset of patients as a measure of clinic chart organization and efficiency.
Statistical Analysis
We required 85 subjects per group to detect an absolute difference of 20% (a = 0.05 and with 80% power) in the proportion of outpatients for whom the estimated 10-year CAD risk could be calculated from charted information, assuming that 80% of the HIV clinic charts would have a calculable 10-year CAD risk.
The between-group analyses planned a priori included rates of chart documentation (that is, information available anywhere in the outpatient chart), measures of CAD risk, treatment rates of modifiable risk factors (that is, hypertension, dyslipidemia, and diabetes mellitus), screening and monitoring practices for risk factors and diseases, and chart organization, which was assessed by the mean time required to retrieve modifiable risk factor information from the chart. We compared groups with Student t test and chi-square analyses, using continuous and binary variables, respectively. Statistical analyses were limited to comparisons involving minimum samples of 15 per group. In addition to between-group analyses, we compared findings with recommendations provided by the Canadian dyslipidemia and hypertension practice guidelines. 18, 19 We used SPSS version 13.0 (SPSS Inc, Chicago, IL, 2005) to perform all statistical analyses. This study was approved by the Capital District Health Authority Research Ethics Board.
Results
We identified 764 potential cases at the mental health clinic from the clinic's patient database. Of these, we selected 260 at random for further screening, of whom 115 were excluded because of inadequate follow-up and 37 because they were not currently taking an antipsychotic drug. Nine other patients were deemed ineligible for various other reasons, leaving 99 mental health patients included in the analysis. Of the 238 patients screened at the HIV clinic, 98 were included in the study. We excluded 140 patients because of inadequate follow-up, no current HAART, a diagnosis of a psychiatric illness, or existing treatment with an antipsychotic drug. Table 1 lists baseline characteristics of the 2 groups. Patients in the mental health clinic were similar in age to those in the HIV clinic but were more likely to be overweight or obese and had more clinic visits yearly. The most frequent psychiatric diagnosis observed in the mental health sample was schizophrenia, followed by BD and schizoaffective disorder. The majority of these patients (77.8%) were prescribed a single newer antipsychotic agent. Only 6.1% were found to be taking more than one antipsychotic drug concurrently.
Ten-Year CAD Risk
The 10-year CAD risk was computable from outpatient chart information for 28% (n = 28) of patients from the mental health clinic and for 90% (n = 88) of patients from the HIV clinic (P < 0.001) ( Figure 1 ). The average 10-year CAD risk estimates for the mental health clinic and the HIV clinic were 11.9% (n = 28) and 9.5% (n = 88), respectively (P = 0.17). Of the 28 mental health patients with a calculable 10-year CAD risk, 50% were considered low-risk (risk estimate £ 10%), 7% were moderate-risk (11% to 19%), and 43% were high-risk (³ 20%). Risk was somewhat lower in the HIV patients (63% low-risk, 15% moderate-risk, and 23% high-risk; c 2 = 4.6, P = 0.10). Figure 2 shows the charting rates for 5 modifiable metabolic risk factors for each group. Among mental health clinic patients, documentation rates for these risk factors ranged from 28% to 70% (mean 53%). For HIV clinic patients, the rate of documentation was 90% or higher for all 5 risk factors. Waist circumference was not recorded in any chart in either clinic, and hemoglobin A 1C was measured for 15% and 9% (P = 0.20) of the mental health clinic and HIV clinic patients, respectively. The prevalence of smoking, dyslipidemia, hypertension, diabetes mellitus, and CAD were each numerically higher in the mental health clinic patients (Table 2) ; however, the differences were not significant. Rates of drug therapy for metabolic and cardiovascular risk factors were different for the use of lipid-lowering therapies (mental health clinic 10.1%, compared with HIV clinic 30.6%, P < 0.001) but were similar for the use of antihypertensives (18.2% and 21.4%, respectively; P = 0.57) and antidiabetics (3.0% and 7.1%, respectively; P = 0.19).
Modifiable Risk Factors
Other than a trend toward higher triglyceride levels in the HIV clinic group, there were no significant between-group differences observed in the lipid profiles (Table 3) . For patients with a documented lipid profile and a calculated 10-year CAD risk (n = 24 for mental health clinic; n = 88 for HIV clinic), 67% in the mental health group and 61% in the HIV group were meeting cholesterol targets according to practice guidelines (c 2 = 0.2, P = 0.63). 18 For patients with a documented blood pressure measurement (n = 69 for mental health clinic; n = 98 for HIV clinic), 68% of those followed by the mental health clinic and 65% of those followed by the HIV clinic were meeting blood pressure targets set forth by current practice guidelines (c 2 = 0.1, P = 0.70). 19 Mean systolic blood pressure was 127 mm Hg, SD 21, for the mental heath group and 126 mm Hg, SD 15, for the HIV group (P = 0.72). Mean diastolic blood pressure was 80 mm Hg, SD 12, and 82 mm Hg, SD 11, in the mental health and HIV groups, respectively (P = 0.30).
Detection and Monitoring
For mental health clinic patients without a documented metabolic disease, screening for dyslipidemia, hypertension, and diabetes mellitus was absent in 65.1% (54/83), 33.7% (28/83), and 40.6% (39/96), respectively. In the HIV group, 100% of patients were screened for hypertension (c 2 = 33.7, P < 0.001) and diabetes mellitus (c 2 = 46.7, P < 0.001), and 88.4% (76/86) were screened for dyslipidemia (c 2 = 51.3, P < 0.001).
Ongoing monitoring of serum lipid levels in patients with CAD, diabetes mellitus, dyslipidemia, and (or) receiving lipid-lowering therapy was absent in 29.4% (5/17) of mental health clinic patients and 0% (0/32) of applicable HIV patients (c 2 = 10.5, P = 0.001). In patients for whom continued blood pressure monitoring was indicated, blood pressure recordings were missing in 8.7% (2/23) of mental health clinic charts and 0% (0/23) of HIV clinic charts (c 2 = 2.1, P = 0.15). In mental health clinic charts, most blood pressure recordings were found in medical consultation notes (26.1%) and emergency visit notes (46.4%), as opposed to mental health clinic progress notes (18.8%). In diabetic mental health patients, plasma glucose levels and hemoglobin A 1C measurements were not recorded for 12.5% (1/8) and 25.0% (2/8), respectively. All patients with diabetes mellitus in the HIV group (7/7) had a documented serum glucose level, yet 28.6% (2/7) did not have a hemoglobin A 1C on record.
Chart Organization and Efficiency
The mean time to gather metabolic risk information from the charts was 128 seconds, SD 12, for mental health clinic charts (n = 40) and 18 seconds, SD 8, for HIV clinic charts (n = 38) (P < 0.001). 
Discussion
In this study, 43% of mental health patients taking antipsychotic drugs long-term were found to be at high risk for CAD. Despite this, and despite the observed 2.4% increase in 10-year CAD risk relative to the HAART-treated HIVpositive control group, we observed several deficiencies in the charting practices for metabolic risk factors and diseases for mental health patients. Information sufficient to calculate 10-year CAD risk was absent in the records of almost three-quarters of the mental health patients. In contrast, this information was readily available to clinicians in 90% of the HIV clinic charts. Documentation rates were also significantly lower in the mental health clinic with regard to the modifiable risk factors (that is, smoking, lipids, blood pressure, BMI, and serum glucose), despite similar or higher rates of dyslipidemia, hypertension, diabetes mellitus, and CAD among mental health patients. Lipid-lowering drug therapy was provided to mental health patients at one-third the rate of HIV-positive patients. Antihypertensive and glucoselowering drug therapies were also prescribed less frequently for the mental health patients, although the differences were not statistically significant. Finally, screening for and monitoring of metabolic diseases and risk factors was consistently inferior in the mental health group.
As far as we are aware, this is the first study to comprehensively evaluate the documentation of screening, treating, and monitoring metabolic risk factors and diseases in a group of psychiatric outpatients. Although disappointing, these findings were expected and parallel the findings of related investigations. In 2 UK studies of inpatients, investigators found that 11.4% of patients taking antipsychotics had undiagnosed glucose impairment or diabetes mellitus and that standard measures were recorded inconsistently (for example, weight was recorded for 18.6%, lipid profile was recorded for 3.5%, and smoking status was "routinely recorded"). 20, 21 Frayne and colleagues 22 found that diabetic patients in the US Veterans Affairs system who had been diagnosed with a mental illness were 38% more likely to have had no monitoring performed for their physical illness and were at 17% and 20% increased odds of poor glycemic and lipemic control, respectively, compared with diabetic patients without a mental illness. In a study of US Medicare claims, Druss and colleagues 23 showed that patients with mental disorders experiencing a myocardial infarction were 20% less likely to be admitted to hospital, 13% less likely to receive reperfusion therapy, and 25% and 32% less likely to undergo percutaneous transluminal coronary angioplasty or coronary artery bypass grafting, respectively, compared with patients without a mental illness. Our results, together with these findings, indicate a disturbing trend of inferior care with respect to metabolic disease and risk factor management in patients with mental illnesses who are taking antipsychotic drugs and are not limited by institutional or regional boundaries.
Resolving this gap in patient care requires an assessment of its contributing factors. The most obvious factors are practice traditions, role delineation, and communications with other health care providers. Stigmatization of patients with mental illnesses within the health care system also needs to be considered. 24 Unlike infectious disease specialists, whose practice has a significant overlap with internal medicine, psychiatrists and their mental health team comembers have traditionally focused on their patients' mental status, mental rehabilitation, home life, and occupational situation. Monitoring and treatment of the physical health needs of their patients has been limited, focusing mostly on well-defined treatment-related adverse effects (for example, white blood cell count with clozapine, movement disorders with traditional antipsychotics, and thyroid function with lithium). In contrast, common health threats, such as cigarette smoking and dyslipidemia, although prevalent in this patient population, have typically received little attention in daily psychiatric practice. The perception that these are matters for general practitioners or the belief that patients are uninterested or unwilling to change may be contributing to this.
The more extensive documentation and monitoring of metabolic problems in the HIV group may be due to a difference in practice tradition-something that can be addressed within health care teams and education programs. Patient access does not appear to be contributing to the problem because mental health clinic patients had an average of 11 visits yearly, compared with 3 visits yearly in the HIV group.
Recent published recommendations facilitate improved efforts in the somatic care of patients with mental illness who are taking antipsychotic drugs long-term. For example, Marder and colleagues 12 have developed, by consensus, a collection of recommendations to support clinicians in monitoring the physical health of patients taking antipsychotics. Regular measurements of BMI, fasting glucose, hemoglobin A 1C , lipids, and electrocardiograms are among their suggestions. At the local level, systems are needed to ensure that this information is measured, documented, and easily accessed for follow-up care. The time required to gather metabolic risk information in this study (in the mental health clinic, 128 seconds; in the HIV clinic, 18 seconds) indicates that an improved system is required for mental health patients at this site.
Several limitations of this study must be recognized. We performed a retrospective chart review, and therefore, the results depended on the accuracy and completeness of chart documentation. No members of the health care team were interviewed. We were unable to determine whether documented serum glucose measurements were fasting levels, and we therefore could not comment on whether glucose management followed practice guidelines. The outpatient clinic chart was our only data source, although this was intentional. As such, we could not determine whether monitoring of the metabolic risk factors and diseases was being performed by another member of the patient's health care team (for example, a family physician). These findings represent the practice of a single mental health clinic and a single HIV clinic and may not reflect practices or standards elsewhere.
Conclusions
Improved efforts are needed in the somatic care of patients with mental illness who are taking antipsychotic drugs long-term. These patients (owing to cigarette smoking, poor diet, lack of exercise, excess weight, and lipid and glucose irregularities) have typically a moderate-to-high risk for developing CAD, but they are less likely than patients at lower risk to receive the recommended monitoring and therapeutic interventions.
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Résumé : Surveillance et prise en charge des facteurs de risque métabolique chez les patients externes prenant des antipsychotiques : une étude contrôlée
Objectif : Évaluer le dépistage, la surveillance et la prise en charge des facteurs de risque et des maladies métaboliques chez les utilisateurs d'antipsychotiques à long terme, relativement aux lignes directrices de la pratique actuelles et aux normes courantes de soins comme les représentait un groupe témoin d'une clinique du VIH.
Méthodes : Nous avons mené un examen rétrospectif des dossiers des patients externes d'une clinique de santé mentale qui prennent des antipsychotiques à long terme (cas) et des patients externes du VIH à qui on a prescrit un traitement antirétroviral très actif (sujets témoins).
Résultats : Nous avons inclus 99 patients d'une clinique de santé mentale et 98 patients du VIH dans l'analyse. Selon les renseignements disponibles dans le dossier des patients externes des cliniques, le risque de coronaropathie sur 10 ans était calculable pour 28 % des patients de la clinique de santé mentale (risque moyen 11,9 %) et pour 90 % des patients du VIH (risque moyen 9,5 %) (c 2 = 77,0; P < 0,001). Les facteurs de risque métabolique étaient moins fréquemment documentés dans les dossiers de la clinique de santé mentale. Tous les patients de la clinique du VIH ont subi des tests de dépistage de l'hypertension et du diabète, et 90 % ont subi des tests pour la dyslipidémie, alors que l'information sur ces 3 affections était absente pour 30 %, 39 %, et 60 % des patients de la clinique de santé mentale, respectivement (P < 0,001 pour tous). La surveillance des maladies était aussi plus détaillée dans les dossiers de la clinique du VIH (par exemple, les lipides de 100 % des patients du VIH étaient surveillés, comparativement à 71 % des patients de la clinique de santé mentale; P = 0,001).
Conclusions :
Il faut des efforts accrus dans le soin somatique des patients souffrant de trouble bipolaire et de schizophrénie qui prennent des antipsychotiques, étant donné qu'ils ont typiquement un risque de modéré à élevé de maladies métaboliques.
